{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:55:42Z","timestamp":1784868942999,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272312"],"award-info":[{"award-number":["82272312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2307004"],"award-info":[{"award-number":["2023YFC2307004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.aohep.2024.101750","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T01:07:54Z","timestamp":1733274474000},"page":"101750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1537-2893","authenticated-orcid":false,"given":"Yiyuan","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.aohep.2024.101750_bib0001","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2024.101750_bib0002","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.aohep.2024.101750_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.aohep.2024.101750_bib0004","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101750_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101750_bib0006","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","article-title":"NASH and hepatocellular carcinoma: immunology and immunotherapy","volume":"29","author":"Pinter","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1 Suppl","key":"10.1016\/j.aohep.2024.101750_bib0007","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2024.101750_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.aohep.2024.101750_bib0009","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101750_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.101215","article-title":"NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment","volume":"47","author":"Targher","year":"2021","journal-title":"Diabetes Metab"},{"issue":"7","key":"10.1016\/j.aohep.2024.101750_bib0011","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.aohep.2024.101750_bib0012","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.aohep.2024.101750_bib0013","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101750_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"issue":"10","key":"10.1016\/j.aohep.2024.101750_bib0015","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.3390\/ijms22105170","article-title":"Alcohol-related liver disease: basic mechanisms and clinical perspectives","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.aohep.2024.101750_bib0016","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.jhep.2023.12.030","article-title":"Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia","volume":"80","author":"Nakano","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2024.101750_bib0017","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0233","article-title":"Changing from NAFLD to MASLD: cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia","author":"Fukunaga","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2024.101750_bib0018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3350\/cmh.2024.0157","article-title":"Changing from NAFLD to MASLD: prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia","volume":"30","author":"Suzuki","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101750_bib0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3350\/cmh.2023.0437","article-title":"Changing from NAFLD to MASLD: similar cumulative incidence of reflux esophagitis between NAFLD and MASLD","volume":"30","author":"Fukunaga","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101750_bib0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2023.0557","article-title":"Changing from NAFLD to MASLD: similar prognosis of patients with HCC under atezolizumab\/bevacizumab treatment between NAFLD and MASLD","volume":"30","author":"Suzuki","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101750_bib0021","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/j.jhep.2023.12.004","article-title":"Changing from NAFLD to MASLD: similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD","volume":"80","author":"Suzuki","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101750_bib0022","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","article-title":"Changing from NAFLD to MASLD: the implications for health-related quality of life data","volume":"80","author":"Hashida","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2024.101750_bib0023","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0264","article-title":"Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease","author":"Suzuki","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2024.101750_bib0024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3350\/cmh.2023.0515","article-title":"Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a sub-analysis of the CLIONE study","volume":"30","author":"Iwaki","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2024.101750_bib0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41416-022-02053-5","article-title":"UK biobank: a globally important resource for cancer research","volume":"128","author":"Conroy","year":"2023","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.aohep.2024.101750_bib0026","first-page":"00914","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"S1542-3565","author":"Kalligeros","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2024.101750_bib0027","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17849","article-title":"Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States","volume":"59","author":"Gawrieh","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.aohep.2024.101750_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172921","article-title":"Characterisation of liver fat in the UK biobank cohort","volume":"12","author":"Wilman","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.aohep.2024.101750_bib0029","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2024.03.045","article-title":"Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort","volume":"81","author":"Chen","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.aohep.2024.101750_bib0030","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41591-023-02383-8","article-title":"Alcohol consumption and risks of more than 200 diseases in Chinese men","volume":"29","author":"Im","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.aohep.2024.101750_bib0031","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathmechdis-031521-030435","article-title":"Recent advances in understanding of pathogenesis of alcohol-associated liver disease","volume":"18","author":"Wu","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.aohep.2024.101750_bib0032","first-page":"30","article-title":"What is the real function of the liver \u201cfunction\u201d tests?","volume":"81","author":"Hall","year":"2012","journal-title":"Ulster Med J"},{"issue":"10","key":"10.1016\/j.aohep.2024.101750_bib0033","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/hepr.13808","article-title":"Metabolic dysfunction-associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients","volume":"52","author":"Inamine","year":"2022","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2024.101750_bib0034","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.aohep.2024.101750_bib0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032604","article-title":"Severity and remission of metabolic dysfunction\u2013associated fatty\/steatotic liver disease with chronic kidney disease occurrence","volume":"13","author":"Gao","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.aohep.2024.101750_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic Liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.aohep.2024.101750_bib0037","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00535-024-02122-x","article-title":"Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"issue":"23","key":"10.1016\/j.aohep.2024.101750_bib0038","first-page":"00409","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"S0953-6205","author":"Mellemkj\u00e6r","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.aohep.2024.101750_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study","volume":"65","author":"Moon","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.aohep.2024.101750_bib0040","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","author":"Lee","year":"2023","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.aohep.2024.101750_bib0041","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach","volume":"51","author":"Tsutsumi","year":"2021","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.aohep.2024.101750_bib0042","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/hepr.13706","article-title":"MAFLD: renovation of clinical practice and disease awareness of fatty liver","volume":"52","author":"Kawaguchi","year":"2022","journal-title":"Hepatol Res"},{"issue":"14","key":"10.1016\/j.aohep.2024.101750_bib0043","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.105.552547","article-title":"Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a Cohort of 163,944 Austrian Adults","volume":"112","author":"Ruttmann","year":"2005","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.aohep.2024.101750_bib0044","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3390\/nu13093173","article-title":"Alcohol and cancer: epidemiology and biological mechanisms","volume":"13","author":"Rumgay","year":"2021","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.aohep.2024.101750_bib0045","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/hepr.14081","article-title":"Association between nonalcholic fatty liver disease and pancreatic cancer: epidemiology, mechanisms, and antidiabetic medication","volume":"54","author":"Sakaue","year":"2024","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.aohep.2024.101750_bib0046","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/hepr.14010","article-title":"Impact of metabolic dysfunction-associated fatty liver disease on the incidence of helicobacter pylori-negative gastric cancer","volume":"54","author":"Nakane","year":"2024","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.aohep.2024.101750_bib0047","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/hepr.13973","article-title":"Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: a multicenter study","volume":"54","author":"Fukunaga","year":"2024","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1016\/j.aohep.2024.101750_bib0048","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/hepr.13795","article-title":"Lean\/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis","volume":"52","author":"Fukunaga","year":"2022","journal-title":"Hepatol Res"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124005337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268124005337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:35:23Z","timestamp":1777782923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268124005337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1665268124005337"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101750","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2024.101750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101750"}}